EN PL
 
EN PL
Current issue
Archive
Online first
About the Journal
Instructions for authors
Books and Events
5/2019 vol. 57
Get citation
EDITORIAL ARTICLE
New era of treatment with biologics in rheumatology – is it time to shift paradigms in treatment with biologics?
Anna Felis-Giemza 1
 
 
 
More details
Hide details
1
Department of Systemic Connective Tissue Diseases, Biological Therapy Center, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
 
 
Online publication date: 2019-10-31
 
 
Reumatologia 2019;57(5):255-256
DOI: https://doi.org/10.5114/reum.2019.89515
 
 
Article (PDF)
References (9)
 
REFERENCES (9)
1.
Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-639.
Google Scholar
 
 
2.
Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19: 2591-2602.
Google Scholar
 
 
3.
Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding – Part I: standard and biologic disease-modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016; 55: 1693-1697.
Google Scholar
 
 
4.
Skorpen CG, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795-810.
Google Scholar
 
 
5.
Goodman SM, Springer B, Guyatt G, et al. ACR/AAHKS Guidelines for Perioperative Management Special Article. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol 2017; 69: 1538-1551.
Google Scholar
 
 
6.
Leon L, Peñuelas M, Candel FJ, et al. Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting. Ther Adv Musculoskelet Dis 2019; 11: 1759720X19878004.
Google Scholar
 
 
7.
Singh JA, Hossain A, Tanjong Ghogomu E, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2016; 5: CD012183.
Google Scholar
 
 
8.
Barroso N, Furst DE. A Case Series on Patients on Tofacitinib in Combination with a Biologic [abstract]. Arthritis Rheumatol 2016; 68 (Suppl 10). https://acrabstracts.org/abstr...- series-on-patients-on-tofacitinib-in-combination-with-a-biologic/ (accessed 27.10.2019).
Google Scholar
 
 
9.
Seror R, Mariette X. Malignancy and the Risks of Biologic Therapies Current Status. Rheum Dis Clin North Am 2017; 43: 43-64.
Google Scholar
 
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
Send by email
Indexes
 
Keywords index
Topics index
Authors index
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
© 2006-2024 Journal hosting platform by Bentus
Scroll to top